Using Artificial Intelligence to prevent Preventable Blindness
WHAT IS DRISTi
DRISTi
Diabetic Retinopathy Screening (DRISTi) (CE Class 1) is an AI product designed to detect the early presence of Diabetic Retinopathy (DR) in patients during eye check up screening process instantaneously. By cutting the cord, and creating a first of its kind, AI on a Chip we have taken DR screeing to the remotest areas of the globe. Our offline solution does not depend on the internet or the cloud and brings Point of Care diagnostics to the forgotten billions who need this service. Diabetic Retinopathy (DR) affects over one third of all people with diabetes and is the leading cause of vision loss. Globally the prevalence of diabetes is increasing rapidly. Since Diabetic Retinopathy (DR) is a progressive disease, early detection and intervention can prevent blindness. Due to the alarming increase of Diabetes, screening for DR every year becomes important.
Process Flowchart
How It Works
AI based Fundus and OCT Analysis
Advanced Diagnostics
Artelus leverages advanced AI technology to enhance the detection and diagnosis of retinal diseases. Our Fundus AI (DRISTi) can capture 4 levels of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME), 16 DR-related pathologies, and 20 other multi-pathologies, providing comprehensive diagnostic capabilities. Additionally, our OCT AI accurately identifies 7 retinal diseases. Both systems are equipped with explainable AI, which generates heatmaps to highlight regions of interest, ensuring transparency and aiding healthcare professionals in making informed clinical decisions.
